The long-acting C5 inhibitor, Ravulizumab, is effective and safe in adult patients with atypical hemolytic uremic syndrome naïve to complement inhibitor treatment

Eric Rondeau; Marie Scully; Gema Ariceta; Tom Barbour; Spero Cataland; Nils Heyne; Yoshitaka Miyakawa; Stephan Ortiz; Eugene Swenson; Marc Vallee; Sung-Soo Yoon; David Kavanagh; Hermann Haller; Sunil Babu; Nilufer Broeders; Nicole Lietar; Fiona Brown; Philip Campbell; Paramit Chowdhury; Theo Kasimatis; Lino Cirami; Leonardo Caroti; Guilia Antognoli; Yahsou Delmas; Vladimir Dobronravov; Anja Gaeckler; Cyril Garrouste; Gregory Greenwood; Siân Griffin; Chiu-Ching Huang; I-Ru Chen; Susan Huang; Jin Seok Kim; Gaetano La Manna; Giorgia Comai; Maria Cappuccilli; Moglie Le Quintrec; Guillaume Jeantet; Iino Fumie; Yosu Luque; Jan Menne; Johan Morelle; Eric Goffin; Anja Muhlfeld; Shashi Nagaraj; Gowthami Arepally; Doyeun Oh; Masayoshi Okumi; Manuel Praga Terente; Elena Gutierréz; Paola Rodriguez; Francois Provot; Ulf Schönermarck; Michael Fischereder; Natalia Ramos Terrada; Barbara Seitz-Polski; Guillaume Favre; Sonia Boyer-Suavet; Maria Vinogradova; Tatiana Kirsanova; Edwin K.S. Wong

doi:10.1016/j.kint.2020.01.035

Back

The long-acting C5 inhibitor, Ravulizumab, is effective and safe in adult patients with atypical hemolytic uremic syndrome naïve to complement inhibitor treatment

Journal article

Open access

Peer reviewed

The long-acting C5 inhibitor, Ravulizumab, is effective and safe in adult patients with atypical hemolytic uremic syndrome naïve to complement inhibitor treatment

Eric Rondeau, Marie Scully, Gema Ariceta, Tom Barbour, Spero Cataland, Nils Heyne, Yoshitaka Miyakawa, Stephan Ortiz, Eugene Swenson, Marc Vallee, …

Kidney International, Vol.97, pp.1287 - 1296

30/06/2020

DOI: https://doi.org/10.1016/j.kint.2020.01.035

Files and links (2)

url

Find in HALView

url

https://doi.org/10.1016/j.kint.2020.01.035View

Published (Version of record) Open

Metrics

1 Record Views

See more details

Details

Title: The long-acting C5 inhibitor, Ravulizumab, is effective and safe in adult patients with atypical hemolytic uremic syndrome naïve to complement inhibitor treatment
Creators - without role: Eric Rondeau - Assistance Publique – Hôpitaux de Paris
Marie Scully - National Institute for Health Research
Gema Ariceta - Vall d'Hebron Hospital Universitari
Tom Barbour
Spero Cataland - The Ohio State University
Nils Heyne - University Children's Hospital Tübingen
Yoshitaka Miyakawa - Saitama Medical University
Stephan Ortiz - Alexion Pharmaceuticals
Eugene Swenson - Alexion Pharmaceuticals
Marc Vallee - Alexion Pharmaceuticals
Sung-Soo Yoon
David Kavanagh - Royal Victoria Hospital
Hermann Haller - Medizinische Hochschule Hannover
Sunil Babu
Nilufer Broeders
Nicole Lietar
Fiona Brown
Philip Campbell
Paramit Chowdhury
Theo Kasimatis
Lino Cirami
Leonardo Caroti
Guilia Antognoli
Yahsou Delmas
Vladimir Dobronravov
Anja Gaeckler
Cyril Garrouste
Gregory Greenwood
Siân Griffin
Chiu-Ching Huang
I-Ru Chen
Susan Huang
Jin Seok Kim
Gaetano La Manna
Giorgia Comai
Maria Cappuccilli
Moglie Le Quintrec - Centre Hospitalier Régional Universitaire [Montpellier]
Guillaume Jeantet
Iino Fumie
Yosu Luque
Jan Menne
Johan Morelle
Eric Goffin - Sorbonne Université
Anja Muhlfeld
Shashi Nagaraj
Gowthami Arepally
Doyeun Oh
Masayoshi Okumi
Manuel Praga Terente
Elena Gutierréz
Paola Rodriguez
Francois Provot
Ulf Schönermarck
Michael Fischereder
Natalia Ramos Terrada
Barbara Seitz-Polski
Guillaume Favre
Sonia Boyer-Suavet
Maria Vinogradova
Tatiana Kirsanova
Edwin K.S. Wong
Publication Details: Kidney International, Vol.97, pp.1287 - 1296
Identifiers: 9935401509311
Academic Unit: Cell souches plasticité cellul régénérat tissulaire immuno des maladies inflamm - IRMB
Language: English
Resource Type: Journal article
Local Fields: hal-03490285